Metabolic syndrome, testosterone, and cardiovascular mortality in men

Journal of Sexual Medicine

Volumn 8, Issue 8, 2011, Pages 2350-2360

  Lin, Jou Wei ^a   Lee, Jen Kuang ^a,b   Wu, Cho Kai ^a   Caffrey, James L ^c   Chang, Man Huei ^d   Hwang, Juey Jen ^a   Dowling, Nicole ^d   Lin, Yu Sheng ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Metabolic Cardiovascular Syndrome; Mortality; Nutrition Surveys; Testosterone Deficiency and Cardiovascular Mortality

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ESTRADIOL BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79960844970     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02343.x     Document Type: Article

References (51)

1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
3. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: Major impact on coronary risk in a population with low cholesterol levels-A prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92.
4. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
5. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999;159:1104-9.
6. Lin JW, Caffrey JL, Chang MH, Lin YS. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality-Cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 2010;95:4258-67.
7. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58-68.
8. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009;5:673-81.
9. Blouin K, Despres JP, Couillard C, Tremblay A, Prud'homme D, Bouchard C, Tchernof A. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005;54:1034-40.
10. Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M, Loukovaara M, Leinonen P, Tuomilehto J. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005;90:1550-6.
11. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-50.
12. Muller M, Aleman A, Grobbee DE, de Haan EH, van der Schouw YT. Endogenous sex hormone levels and cognitive function in aging men: Is there an optimal level? Neurology 2005;64:866-71.
13. Svartberg J, von Muhlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004;19:657-63.
14. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 2008;108:272-80.
15. Lee KK, Fortmann SP, Fair JM, Iribarren C, Rubin GD, Varady A, Go AS, Quertermous T, Hlatky MA. Insulin resistance independently predicts the progression of coronary artery calcification. Am Heart J 2009;157:939-45.
16. Haider A, Gooren LJ, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 2010;118:167-71.
17. CDC. National Center for Health Statistics (NCHS). Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: Programs and collection procedures. Vital Health Stat 1 1994;32:1-407.
18. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA. Androgens and diabetes in men: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234-8.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
20. CDC, National Center for Health Statistics (NCHS). 2010. The Third National Health and Nutrition Examination Survey 1988-1994. NHANES III linked mortality public-use file. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Hyattsville, Maryland. Available at: (accessed November 1, 2010).
21. Petra PH. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 1991;40:735-53.
22. CDC, National Center for Health Statistics (NCHS). 2006. The Third National Health and Nutrition Examination Survey 1988-1994. Suplus Sera Laboratory Component: Racial/Ethnic Variation In Sex Steroid Hormone Concentrations Across Age In US Men. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Hyattsville, Maryland. Available at: (accessed September 1, 2010).
23. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
24. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: Preliminary estimates. Natl Vital Stat Rep 2001;49:1-32.
25. Shabsigh R. Testosterone therapy in erectile dysfunction. Aging Male 2004;7:312-8.
26. Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: Economic and quality-of-life impact. J Sex Med 2007;4(Pt 1):1056-69.
27. Haring R, Volzke H, Steveling A, Krebs A, Felix SB, Schöfl C, Dörr M, Nauck M, Wallaschofski H. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494-501.
28. Katabami T, Kato H, Asahina T, Hinohara S, Shin T, Kawata T, Ohta A, Iwamoto T, Tanaka Y. Serum free testosterone and metabolic syndrome in Japanese men. Endocr J 2010;57:533-9.
29. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
30. Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in Men. Diabetes Care 2010;33:1618-24.
31. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-80.
32. Kirschner MA, Samojlik E. Sex hormone metabolism in upper and lower body obesity. Int J Obes 1991;15(suppl 2):101-8.
33. Hammoud AO, Gibson M, Peterson CM, Hamilton BD, Carrell DT. Obesity and male reproductive potential. J Androl 2006;27:619-26.
34. Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am 2003;32:895-914.
35. Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-200.
36. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009;30:23-32.
37. Lee YC, Liu CC, Huang CN, Li WM, Wu WJ, Yeh HC, Wang CJ, Huang CH, Huang SP. The potential impact of metabolic syndrome on erectile dysfunction in aging Taiwanese males. J Sex Med 2010;7:3127-34.
38. Hernández-Mijares A, García-Malpartida K, Solá-Izquierdo E, Bañuls C, Rocha M, Gómez-Martínez MJ, Mármol R, Víctor VM. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010;7:1954-64.
39. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.
40. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
41. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.
42. Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, Kanarek N, Feinleib M, Michos ED, Dobs A, Platz EA. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010;171:583-92.
43. Lin JW, Chang YC, Li HY, Chien YF, Wu MY, Tsai RY, Hsieh YC, Chen YJ, Hwang JJ, Chuang LM. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney disease in Taiwanese. Diabetes Care 2009;32:2294-6.
44. Huang KC, Lee LT, Chen CY, Sung PK. All-cause and cardiovascular disease mortality increased with metabolic syndrome in Taiwanese. Obesity (Silver Spring) 2008;16:684-9.
45. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
46. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-503.
47. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart 2004;90:446-7.
48. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24:909-15.
49. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008;101:618-24.
50. Raynaud JP. Testosterone deficiency syndrome: Treatment and cancer risk. J Steroid Biochem Mol Biol 2009;114:96-105.
51. Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011;2011. pii: 471584. Epub 2010 Aug 10.